YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer: A Critical Therapeutic Target

YY1 Is Pivotal in the Control of the Pathogenesis and Drug Resistance of Cancer: A Critical Therapeutic Target describes the current state-of-the-art of the transcription factor YY1 that is overexpressed in the majority of cancers and a central factor that regulates all of the major features and characteristics of human cancers. This book emphasizes the biochemical, molecular and genetic underlying mechanisms by which YY1 regulates its pro-cancerous activities. In addition, it also describes the role of YY1 in the regulation of tumor cell resistance to conventional chemo and immunotherapies and the important role of inhibiting YY1 in cancer.

This book is a valuable source for cancer researchers, oncologists and several members of medical and biomedical field who are interested in understanding further the role of YY1 in cancer.

• Provides a thorough understanding of the underlying mechanisms by which YY1 regulates cancer cell phenotype and unique characteristics
• Discusses the novel mechanisms of YY1 regulation of tumor cell resistance and means to overcome resistance
• Encompasses new examples of newly developed non-toxic and selective inhibitors targeting YY1

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).